drug-eluting versus bare-metal stent for treatment of saphenous vein grafts a meta-analysis药物洗脱与裸金属支架治疗隐静脉移植一个荟萃分析.pdfVIP

Drug-Eluting versus Bare-Metal Stent for Treatment of Saphenous Vein Grafts: A Meta-Analysis 1,2 3 4 5 6 Pascal Meier , Emmanouil S. Brilakis , Roberto Corti , Guido Knapp , Mehdi H. Shishehbor , Hitinder S. Gurm1,2* 1 University of Michigan Medical Center, Ann Arbor, Michigan, United States of America, 2 Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan, United States of America, 3 Division of Cardiovascular Diseases, Veterans Affairs North Texas Healthcare System, Dallas, Texas, United States of America, 4 Department of Cardiology, University Hospital Zurich, Zurich, Switzerland, 5 Department of Statistics, TU Dortmund University, Dortmund, Germany, 6 Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, United States of America Abstract Background: Saphenous vein grafts develop an aggressive atherosclerotic process and the efficacy of drug eluting stents (DES) in treating saphenous vein graft (SVG) lesions has not been convincingly demonstrated. The aim of this study was to review and analyze the current literature for controlled studies comparing DES versus bare metal stents (BMS) for treatment of SVG stenoses. Methodology/Principal Findings: We searched several scientific databases and conference proceedings up to March 15, 2010 for controlled studies comparing target vessel revascularization (TVR) between DES and BMS. Summary odds ratios (OR) for the primary endpoint TVR and secondary endpoints infarction, stent thrombosis and death were calculated using random-effect models. A total of 29 studies (3 randomized controlled trials RCT) involving 7549 (202 in RCT) patients were included. The need for target vessel revascularization in the DES group tended to be lower compared to BMS for the 3 RCT